Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies

Nature Aging, Journal Year: 2023, Volume and Issue: 3(6), P. 661 - 669

Published: April 27, 2023

Abstract Blood phosphorylated tau (p-tau) biomarkers, at differing sites, demonstrate high accuracy to detect Alzheimerʼs disease (AD). However, knowledge on the optimal marker for identification across AD continuum and link pathology is limited. This partly due heterogeneity in analytical methods. In this study, we employed an immunoprecipitation mass spectrometry method simultaneously quantify six (p-tau181, p-tau199, p-tau202, p-tau205, p-tau217 p-tau231) two non-phosphorylated plasma peptides a total of 214 participants from Paris Lariboisière Translational Biomarkers Aging Dementia cohorts. Our results indicate that p-tau217, p-tau231 p-tau205 are forms best reflect AD-related brain changes, although with distinct emergences along course correlations features—amyloid tau. These findings support differential association blood p-tau variants pathology, our offers potential tool staging clinical trials.

Language: Английский

---

Biomarker-based staging of Alzheimer disease: rationale and clinical applications

Nature Reviews Neurology, Journal Year: 2024, Volume and Issue: 20(4), P. 232 - 244

Published: March 1, 2024

Language: Английский

---

Blood Biomarkers in Neurodegenerative Diseases

Neurology, Journal Year: 2023, Volume and Issue: 101(4), P. 172 - 180

Published: March 6, 2023

Blood-based biomarkers offer a major advance in the clinical evaluation of neurodegenerative diseases. Currently, research studies have reported robust assays blood markers for detection amyloid and tau pathologies specific to Alzheimer disease (amyloid-β peptides, p-tau) nonspecific neuronal (neurofilament light, β-synuclein, ubiquitin-C-terminal-hydrolase-L1) glial degeneration (glial fibrillary acidic protein) that can measure key pathophysiologic processes several In near future, these may be used screening, diagnosis, or treatment response monitoring. diseases been rapidly implemented research, they potential enter use soon different settings. this review, we will describe main developments their implications general neurologist.

Language: Английский

---

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid

Alzheimer s & Dementia, Journal Year: 2024, Volume and Issue: 20(5), P. 3179 - 3192

Published: March 16, 2024

With the availability of disease-modifying therapies for Alzheimer's disease (AD), it is important clinicians to have tests aid in AD diagnosis, especially when presence amyloid pathology a criterion receiving treatment. High-throughput, mass spectrometry-based assays were used measure %p-tau217 and beta (Aβ)42/40 ratio blood samples from 583 individuals with suspected (53% positron emission tomography [PET] positive by Centiloid > 25). An algorithm (PrecivityAD2 test) was developed using these plasma biomarkers identify brain amyloidosis PET. The area under receiver operating characteristic curve (AUC-ROC) (0.94) statistically significantly higher than that p-tau217 concentration (0.91). AUC-ROC PrecivityAD2 test output, Amyloid Probability Score 2, 0.94, yielding 88% agreement Diagnostic performance APS2 similar ethnicity, sex, age, apoE4 status. showed strong clinical validity, excellent

Language: Английский

---

Revised criteria for the diagnosis and staging of Alzheimer’s disease

Nature Medicine, Journal Year: 2024, Volume and Issue: 30(8), P. 2121 - 2124

Published: June 28, 2024

Language: Английский

---